REG - IP Group PLC - Appointment of Chair Designate

IPAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260507:nRSG3153Da&default-theme=true

RNS Number : 3153D  IP Group PLC  07 May 2026

 FOR RELEASE ON  7 May 2026

Appointment of Michael Queen as Chair Designate

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in
breakthrough science and technology companies with the potential to create a
better future for all, is delighted to announce the appointment of Michael
Queen as Non-executive Director and Chair Designate. The appointment concludes
the Chair succession process announced last year and supports IP Group's
continued focus on long‑term value creation and scaling institutional
capital.

Michael will succeed Sir Douglas Flint, CBE, as Chair of the Board following
IP Group's Annual General Meeting on 18 June 2026 when Sir Douglas will retire
from the Board after almost eight years of service.

Greg Smith, Chief Executive of IP Group, said: "I am delighted to welcome
Michael to the Board at a time of growing opportunity for IP Group. He brings
deep investment and leadership experience, with a strong track record in
scaling institutional capital platforms, which aligns closely with our
strategy as we continue to grow funds under management and support our
portfolio through their next phase of development. On behalf of the Board and
our colleagues, I would also like to thank Sir Douglas for the enormous
contribution he has made to IP Group over many years and to wish him every
success in the future."

Michael Queen said: "IP Group is a nationally significant platform that
invests in and supports leading scientific innovation. I'm excited to be given
the opportunity to chair the Group as it scales its model and I look forward
to working with the team to help deliver value for all stakeholders."

Sir Douglas Flint said: "I look forward to working with Michael over the next
few weeks to support his transition into the role of Chair following the AGM.
Michael's deep knowledge of private markets and venture investment will be
invaluable to support the Group's realisation of value from the portfolio and
its refresh, as will his understanding of the University sector in the UK. I
will leave the Group as a loyal and committed shareholder reflecting on the
privilege it has been to work alongside such a talented executive team and
Board. I would like to thank the Board, the leadership team and the wider IP
Group team for their commitment and support throughout my tenure."

Michael was formerly Chief Executive of 3i Group plc, the global investment
company where after 25 years he retired in 2012 having developed 3i's
activities in the infrastructure sector through founding 3i Infrastructure
plc. He is currently Chair of Coller Capital Ltd, a UK based international
Private Equity Group, Pro-Chancellor of the University of Surrey, Chair of
Thames Tideway Tunnel and a non-executive director of TAQA, a Middle East
based industrial group.

He has extensive experience in the public and private sectors, having been a
member of the Prime Ministers Business Advisory Group from 2010-2012 and
having been seconded to HM Treasury in 1994 to help to develop the potential
for the Private Finance Initiative in the NHS as Head of the NHS Private
Finance Unit. In 2002 Michael was Chairman of the British Venture Capital
Association and he was also President of Surrey 100, a Business Angel Group
attached to the University of Surrey from 2012 to 2018. Michael has a BA
(Hons) Industrial Economics from Nottingham University and is a Chartered
Accountant.

This announcement is made pursuant to Listing Rule 6.4.6R. There are no other
details required to be disclosed under Listing Rule 6.4.8R.

For more information, please contact:

 

 IP Group plc                       www.ipgroupplc.com
 Liz Vaughan-Adams, Communications  +44 (0) 20 7444 0062/+44 (0) 7967 312125
 Portland
 Lewis Bendall-Craft                +44 (0) 7931 973950

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most
active UK based, early stage science and technology investor, we develop and
support some of the world's most exciting businesses in healthtech, deeptech
and cleantech. Including through Parkwalk, the UK's largest growth EIS fund
manager, we back world-changing innovation emerging in leading universities
and research institutions. Our specialist investment team combines sector
expertise with an international approach. Together we have a strong track
record of success, having backed high-profile companies including Oxford
Nanopore Technologies plc, Hinge Health, Featurespace, First Light Fusion,
Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock
Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com
(http://www.ipgroupplc.com/) .

 

ENDS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAAKABNOBKDKPK



            Copyright 2019 Regulatory News Service, all rights reserved